Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.
Cellectis unveiled groundbreaking research data on gene-editing technologies at the upcoming Society of Gene and Cell Therapy annual meeting in New Orleans (May 13-17, 2025). The company presented two significant innovations:
1. TALEN-Mediated Non-viral Transgene Insertion:
- Successfully combined TALEN gene editing with non-viral delivery methods
- Demonstrated high efficiency in T-cells and blood stem cells
- Showed better cell fitness and stability compared to traditional viral methods
- Addresses challenges of viral methods like manufacturing limits and toxicity risks
2. TALE Base Editors (TALEB) Development:
- Created new method for precise C-to-T DNA conversion
- Achieved efficient editing without DNA strand damage
- Showed no detectable off-target editing in primary cells
- Developed system to assess editing efficiency across different sequences
These breakthroughs could advance treatments for cancer, autoimmune diseases, and genetic disorders. The complete research data will be available on Cellectis' website when the event begins.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.
Key pipeline updates include:
- UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease Designations
- UCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025
- Three active programs in collaboration with AstraZeneca
Notable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing platforms for cell and gene therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after US market close.
The company will host an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET to discuss the financial results and provide business updates. Investors can access the call through domestic (+1-800-225-9448) or international (+1-203-518-9708) dial-in numbers using Conference ID: CLLS24.
Cellectis (CLLS) has released its monthly share capital and voting rights report as required by Article 223-16 of the French financial markets authority's General Regulation. The company's shares are listed on Euronext Growth under ISIN code FR0010425595.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
